Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07121946
PHASE1

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Sponsor: LTZ Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma

Official title: A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

42

Start Date

2026-01-29

Completion Date

2028-02

Last Updated

2026-02-10

Healthy Volunteers

No

Interventions

BIOLOGICAL

LTZ-301

LTZ-301 will be dosed IV, in initial 28 day cycles. First cycle dosing is every week. Second through fifth cycles are dosed every 2 weeks. Sixth cycle and beyond are 21 day cycles, and are dosed once every 3 weeks.

BIOLOGICAL

LTZ-301

LTZ-301will be dosed IV, as above

BIOLOGICAL

LTZ-301

LTZ-301will be dosed IV, as above

Locations (5)

City of Hope

Duarte, California, United States

Washington University School of Medicine

St Louis, Missouri, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Tennessee Oncology

Nashville, Tennessee, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States